The guanine-based purinergic system: the tale of an orphan neuromodulation

dc.contributor.authorLiberto, Valentina Di
dc.contributor.authorMudò, Giuseppa
dc.contributor.authorGarozzo, Roberta
dc.contributor.authorFrinchi, Monica
dc.contributor.authorFernández Dueñas, Víctor
dc.contributor.authorIorio, Patrizia Di
dc.contributor.authorCiccarelli, Renata
dc.contributor.authorCaciagli, Francesco
dc.contributor.authorCondorelli, Daniele F.
dc.contributor.authorCiruela Alférez, Francisco
dc.contributor.authorBelluardo, Natale
dc.date.accessioned2019-09-26T15:15:35Z
dc.date.available2019-09-26T15:15:35Z
dc.date.issued2016-06-19
dc.date.updated2019-09-26T15:15:35Z
dc.description.abstractGuanine-based purines (GBPs) have been recently proposed to be not only metabolic agents but also extracellular signaling molecules that regulate important functions in the central nervous system. In such way, GBPs-mediated neuroprotection, behavioral responses and neuronal plasticity have been broadly described in the literature. However, while a number of these functions (i.e., GBPs neurothophic effects) have been well-established, the molecular mechanisms behind these GBPs-dependent effects are still unknown. Furthermore, no plasma membrane receptors for GBPs have been described so far, thus GBPs are still considered orphan neuromodulators. Interestingly, an intricate and controversial functional interplay between GBPs effects and adenosine receptors activity has been recently described, thus triggering the hypothesis that GBPs mechanism of action might somehow involve adenosine receptors. Here, we review recent data describing the GBPs role in the brain. We focus on the involvement of GBPs regulating neuronal plasticity, and on the new hypothesis based on putative GBPs receptors. Overall, we expect to shed some light on the GBPs world since although these molecules might represent excellent candidates for certain neurological diseases management, the lack of putative GBPs receptors precludes any high throughput screening intent for the search of effective GBPs-based drugs.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec666906
dc.identifier.issn1663-9812
dc.identifier.pmid27378923
dc.identifier.urihttps://hdl.handle.net/2445/140855
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fphar.2016.00158
dc.relation.ispartofFrontiers in Pharmacology, 2016, vol. 7, p. 158
dc.relation.urihttps://doi.org/10.3389/fphar.2016.00158
dc.rightscc-by (c) Liberto, Valentina Di et al., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationPurines
dc.subject.classificationTrifosfat de guanosina
dc.subject.classificationAdenosina
dc.subject.otherPurines
dc.subject.otherGuanosine triphosphatase
dc.subject.otherAdenosine
dc.titleThe guanine-based purinergic system: the tale of an orphan neuromodulation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
666906.pdf
Mida:
360.59 KB
Format:
Adobe Portable Document Format